5,6-dihydroxy-1-(2-imidazolinyl)tetralin has been researched along with Hypertension in 1 studies
*Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brondyk, H; Buckner, SA; Bush, EN; DeBernardis, JF; Kyncl, JJ | 1 |
1 other study(ies) available for 5,6-dihydroxy-1-(2-imidazolinyl)tetralin and Hypertension
| Article | Year |
|---|---|
Novel adrenergic compounds. I. Receptor interactions of ABBOTT-54741 [(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthtyl)imidazoline], an alpha-adrenergic agonist.
Topics: Adrenergic Agonists; Animals; Aorta; Dogs; Hemodynamics; Hypertension; Imidazoles; In Vitro Techniques; Male; Naphthalenes; Pulmonary Artery; Rabbits; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Saphenous Vein; Tetrahydronaphthalenes | 1989 |